- VETARYS and Antigenesis Biologics announced a research collaboration and an option for an exclusive license to develop a canine cancer immunotherapy.
- The investigational treatment combines two immunotherapeutic approaches into a single fusion protein designed to target solid tumors in dogs.
- The combination demonstrated encouraging tumor reduction and survival results in a preclinical mouse melanoma model, according to the companies.
- The development program aims to create a subcutaneous treatment that could be administered by primary care veterinarians.
- The collaboration seeks to expand access to canine cancer treatment while complementing the services provided by veterinary oncology specialists.
VETARYS has announced a research collaboration with Antigenesis Biologics to develop a novel combination immunotherapy for treating solid tumors in dogs, representing an effort to expand therapeutic options in veterinary oncology.
The partnership, announced October 26 during the 2026 Boston Animal Health, Nutrition and Technology Innovation (AHNTI) Conference, includes an option for VETARYS to obtain an exclusive license for the investigational treatment.
The therapy is being developed by Antigenesis Biologics as a fusion protein that combines two immunotherapeutic approaches into a single treatment.
Building on Advances in Human Cancer Immunotherapy
Antigenesis Biologics is applying advances in human immuno-oncology to the development of antibody-based therapeutics for companion animals, with canine cancer as its initial focus.
The investigational fusion protein is designed to combine two immunotherapies that have shown encouraging results when used together in preclinical research.
According to VETARYS, the combination demonstrated improvements in survival and tumor shrinkage in a mouse model of severe melanoma.
While these findings provide an early foundation for further development, the companies have not reported clinical efficacy or safety results in dogs in the announcement.
Additional research will be needed to establish whether the approach can deliver comparable benefits in canine cancer patients.
Potential to Expand Cancer Treatment Beyond Specialty Practices
A central objective of the collaboration is to develop a cancer immunotherapy that could be administered subcutaneously by primary care veterinarians.
This approach could potentially increase treatment accessibility for dogs whose owners have limited access to veterinary oncology specialists.
Peter Hanson, Chief Scientific Officer at VETARYS, noted that conventional canine cancer treatments, including chemotherapy and radiation, can have variable effectiveness and may produce significant adverse effects.
The company sees an opportunity to develop immunotherapy options that complement existing oncology treatments while expanding the role of general veterinary practices in cancer care.
By targeting a treatment format suitable for administration outside specialty oncology centers, the development program could help address geographic and logistical barriers to veterinary cancer treatment.
Early-Stage Development With Potential Clinical Applications
The collaboration reflects growing interest in translating immunotherapy technologies developed for human medicine into veterinary applications.
Although immunotherapy has become an important treatment strategy in human oncology, the development and availability of comparable treatments for dogs remain more limited.
The VETARYS–Antigenesis program is focused on evaluating whether a combination approach can offer meaningful therapeutic benefits for canine solid tumors.
The companies have not disclosed a development timeline, anticipated clinical trial dates or a projected regulatory submission in the announcement.
Further preclinical and clinical evaluation will be necessary to determine the treatment’s safety, effectiveness and potential role alongside established canine oncology therapies.
Additional Information
For more information about the companies and their development programs, visit:
Information sourced from VETARYS’ October 26, 2026, press release announcing its research collaboration with Antigenesis Biologics.
